Cerluten
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
Cerluten is a peptide bioregulator complex (A-5) derived from the cerebral cortex tissue of young calves, developed by Professor Vladimir Khavinson and colleagues to support central nervous system function. It is part of a broader class of tissue-specific peptide bioregulators that aim to regulate cellular metabolism and gene expression in the brain.
Like other Khavinson peptides, Cerluten is taken in oral capsule form, typically in short courses. Most evidence comes from preclinical studies and limited clinical observation in Russia and Eastern Europe. Cerluten is not approved by any major Western regulator for human therapeutic use.
How it works
The mechanism proposed by Khavinson’s research suggests that brain-specific peptides interact with cellular DNA to regulate gene expression and protein synthesis in neural tissue. Preclinical evidence indicates that peptide complexes from brain tissue may support serotonin expression in cortical cells and help regulate oxidative metabolism in the brain.
In theory, these peptides could promote neuronal resilience and support normal CNS function, though the precise mechanisms in humans are not established. Most mechanistic data derive from cell culture and animal models.
Reported benefits
- Support for cognitive function and mental clarity (studied in limited clinical trials)
- Potential reduction in neuroinflammation and oxidative stress in brain tissue (preclinical evidence)
- Possible benefits for age-related cognitive decline (anecdotal reports)
These are reported effects based on limited human data and preclinical research, not established therapeutic outcomes.
Considerations & side effects
Because clinical evidence for Cerluten in humans is sparse, its long-term safety profile is not well characterized. Reported side effects in available studies are uncommon and generally mild, including occasional headache, mild dizziness, or transient mood changes.
Product quality and purity in the research-chemical market vary widely. Cerluten is not a substitute for medical diagnosis or treatment of neurological conditions. Individuals with brain or nervous system disorders should consult a qualified clinician before use.
Frequently asked
What is Cerluten?
A peptide bioregulator complex derived from calf brain tissue, developed to support central nervous system function. It is a multi-peptide preparation (peptide complex A-5) based on Khavinson's peptide-bioregulator model.
How is Cerluten taken?
Cerluten is typically administered as oral capsules, often in short courses (10–20 days) followed by rest periods, according to traditional Khavinson protocols.
Is Cerluten FDA-approved?
No. Cerluten is not approved by the FDA, EMA, or other major regulators for therapeutic use in humans. It is sold for research purposes only and has primarily been studied in Russia and Eastern Europe.
What does the research show?
Preclinical and clinical studies suggest that brain-derived peptides may support neuronal health and serotonin expression. A small clinical study in 2003–2004 reported improvements in patients with chronic neurological conditions, but human data remains limited.
Are there side effects?
Reported adverse effects are rare in available studies; mild reactions like headache or dizziness have been occasionally noted. Because human trials are scarce, long-term safety is not well established.
References
Related compounds
AEDP tetrapeptide brain cortex bioregulator. Supports neuroprotection, cognitive function, and nerve regeneration through epigenetic regulation.
Standardized neuropeptide preparation with neurotrophic and neuroprotective properties. Used clinically in 50+ countries for stroke recovery, traumatic brain injury, and dementia treatment.
Small peptide derived from angiotensin IV. Potent cognitive enhancer that promotes synaptic connectivity via HGF/MET signaling. Highly experimental with limited human data.